Track record · closed signal

Merck & Company Inc (MRK) — closed signal from April 17, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 16, 2026 — +10% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$112.38 – $116.32Entry zone — fair-value band

$116.08Published — price the day we called it

$127.92Target — the price the thesis aimed for

$130.29Peak — highest point inside the window, not a realized return

$127.63Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 73 days.

At window close

+10%

realized, from the publication price to the last close inside the window

Peak gain

+12.2%

peak, from the publication price — not a realized return

S&P 500, same window

+6%

SPY over the identical days, dividend-adjusted

Window close

$127.63

last close inside the window, ended July 16, 2026

Peak price

$130.29

peak on June 30, 2026 — not a realized return

Days to target

The thesis — published April 17, 2026

Predicted growth

+11%

over the measurement window

Target price

$127.92

the price the thesis aimed for

Entry zone

$112.38 – $116.32

the fair-value band we waited for

Price at publication

$116.08

published April 17, 2026

Confidence

75%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck looks like a steadier healthcare pick because its near-term story depends on real drug news, not market hype. EU approval for clesrovimab and a priority review for ifinatamab boost visibility for upcoming products. Shares appear sold-off, and solid profits and valuation give some protection. If sentiment improves, a 0-3 month rebound is plausible.

Primary drivers

New approval and priority review increase near-term product visibility
Good valuation and profitability reduce downside risk
Adds healthcare balance to a tech-heavy mix
Recent selling leaves room to recover if price steadies

How it played out

MRK: target reached in 73 days

Lyra published MRK at $116.08 with an expected 11% gain and a $127.92 target over the short-term window. The thesis pointed to new product approval and priority review, solid profitability and valuation, healthcare balance, and room for a rebound after recent selling.

The price reached $127.92 in 73 days. It later peaked at $130.29 on June 30, a 12.2% gain. That was above the target. MRK ended the window at $127.63, still below its peak. The published price thesis played out within the measurement window.

What happened during the window

On April 30, Merck reported first-quarter sales of $16.3 billion, up 5%. On May 5, Merck completed its acquisition of Terns Pharmaceuticals.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals